Adalvo has completed pilot bioequivalence studies for generic Letermovir film-coated tablets. The programme will now advance into pivotal bioequivalence studies, ahead of filings in multiple markets.
As a high-barrier antiviral with limited development competition, Letermovir represents a valuable opportunity for partners seeking differentiated specialty products.
Adalvo is using its in-house expertise and extensive global supply network to meet the dual challenges of API sourcing and manufacturing complexity, ensuring partners are ready for Day-1 launch opportunities.
For partnership and licensing enquiries, or to see Adalvo’s full portfolio of antiviral therapies, contact enquiries@adalvo.com